SOFINNOVA-PARTNERS
14.12.2021 16:02:08 CET | Business Wire | Press release
Sofinnova Partners , a leading European life sciences venture capital firm based in Paris, London and Milan, announced today $5 million in seed funding for Endoron Medical (“Endoron”) to accelerate the development of the company’s endograft stapling solution for endovascular repair of abdominal aortic aneurysms (“AAA”). This is the third investment from its medtech acceleration fund, Sofinnova MD Start III.
Proceeds from the financing round will provide working capital to accelerate the full validation of the Endoron’s EndoStapling catheter-based solution. The funds will also be used to de-risk the regulatory strategy in preparation for the initial clinical experience, which will aim to establish safety, feasibility, and efficacy of the company’s patented endovascular suturing technology. In keeping with Sofinnova MD Start’s unique approach as a hands-on company builder, Cécile Dupont, Senior Associate and Program Director at Sofinnova Partners, will join the Endoron management team to bring greater operational and strategic support to accelerate the development of the company's highly disruptive technology.
Lukas Guenther, M.D., Partner at Sofinnova Partners and a key member of the Sofinnova MD Start III Fund, commented: “More than 400,000 new patients in the U.S. and Europe are diagnosed with AAA disease every year, with 42% presenting complex anatomies. These patients undergo endovascular repair, but still face long-term complications such as endograft migration, endoleaks, neck dilation, and consequently reinterventions. Endoron’s innovative technology has the potential to radically change the way we perform endovascular repair in AAA patients today, and to dramatically reduce complications and reinterventions.”
Ronit Harpaz, Co-Founder and Chief Executive Officer of Endoron, said: “The Sofinnova MD Start team are the go-to investors in the medtech domain and are also seasoned medtech entrepreneurs who bring a wealth of operational experience working in high-growth companies like ours. With their support, I am confident we will quickly reach key clinical and regulatory inflection points as we work to bring our EndoStapling technology to the clinic.”
Founded in 2019, Endoron Medical builds on an invention from Prof. Ron Karmeli (Hadassah Hospital, Jerusalem), who is co-founder and Chief Medical Officer of the Company.
Endoron’s technology has been developed to overcome the challenges associated with the sealing and fixation of endografts used for the minimally invasive repair of AAA in challenging anatomies and to avoid highly invasive, high-mortality open surgery, which is still being used in that case.
The Endoron solution is meant to secure an endograft's fixation and to improve sealing mechanisms. In addition, the stapling mechanisms developed by Endoron can be used to repair endovascular grafts that have migrated away from the implant site and have developed endoleaks. In such cases, augmented fixation and sealing is required to regain or maintain effective aneurysm exclusion.
The Sofinnova MD Start team is the only medtech accelerator in Europe and is comprised of seasoned medtech entrepreneurs and investors with extensive experience in high-growth early-stage medical device companies, and a successful track record of catalyzing innovative technology from conception to the clinic. The fund has made two other investments to date: Gradient Denervation Technologies and Moon Surgical.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply-established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: www.sofinnovapartners.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005366/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Arini Announces Final Close of Inaugural Direct Lending Fund, Targeting Over $4 Billion of Deployment21.10.2026 09:00:00 CEST | Press release
Arini, an alternative asset manager with $22 billion in assets under management as of 31 August 2026, today announces the final close of Arini Direct Lending Fund I. The Fund and related vehicles are targeting deployment of over $4 billion, including anticipated leverage, making it among the largest debut European direct lending funds ever raised. Arini has built a sizeable initial portfolio throughout the fundraise, focusing on senior secured loans to borrowers demonstrating recurring and underwritable cash flow profiles and operating in industries with limited risk of disruption. Total deployment for the strategy is now approaching $2 billion across a range of sectors and geographies, alongside founder-led, family-owned and sponsor-backed businesses. This scale of deployment, in conjunction with Arini’s highly selective underwriting standards, demonstrates the depth of the European middle market opportunity set. Unlike in the US, banks in Europe have a dominant market share in corpor
LemFi Launches Its Biggest Product Expansion Yet Alongside a New Global Brand, ‘Ambition has no passport’21.10.2026 09:00:00 CEST | Press release
LemFi launches the biggest product expansion in its history, adding UK savings, credit, and data eSIM in 100+ destinations A rebuilt app brings transfers, savings, credit and connectivity together in one platform for people building financial lives across borders New global brand, “Ambition has no passport”, reflects LemFi’s evolution from remittances into a broader financial platform serving more than two million customers LemFi, the financial platform for people building lives across borders, today announced the launch of its new global brand platform, “Ambition has no passport”, alongside a completely rebuilt app, launching the largest product expansion in its history. More than two million customers use LemFi to move money to more than 30 countries, with over $2 billion in monthly transaction volume, and the company plans to add more countries next year. The expanded platform now includes savings and credit in the UK, eSIMs in more than 100 destinations, alongside LemFi’s existing
Skechers Wins Major Victory Against Kizik in Patent Infringement Suit21.10.2026 09:00:00 CEST | Press release
Munich Court States that Kizik’s Patent Infringement Case Against Skechers is “Largely Unfounded” Skechers U.S.A., Inc. (“Skechers”), the third largest footwear company in the world and leader in hands-free footwear technology, announced today that it won a major legal and commercial victory in a patent infringement lawsuit filed by Fast IP, LLC (“Kizik”) against Skechers before the Unified Patent Court (“UPC”) in Munich. Skechers, the market leader in hands-free footwear, sells thousands of styles of hands-free shoes worldwide under its Slip-ins and Swift Fit trademarks. In 2025, Kizik sued Skechers at the UPC for alleged patent infringement involving four of its thousands of hands-free styles. Skechers won on three of the four styles, with the fourth being a minor and commercially insignificant style for Skechers. In its ruling, the Munich Court stated that Kizik’s infringement claims are “largely unfounded.” Skechers’ leading hands-free footwear position globally is the result of it
AI and Multichannel Communication Come to Italian Municipalities21.10.2026 09:00:00 CEST | Press release
ANCIcomunicare and Audiencerate join forces on a new platform for local authorities, built on Microsoft AI and Cloud, distributed by Postel, a Poste Italiane Group company, and available through MEPA ANCIcomunicare and Audiencerate are partnering to provide Italian municipalities and local authorities with a new platform dedicated to data management and multichannel communication. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019549522/en/ ANCIcomunicare and Audiencerate launch a partnership to bring Italian municipalities a platform that simplifies data management and digital communication with citizens across all channels. The solution enables municipalities to manage, through a single digital system, communication campaigns aimed at citizens and businesses across multiple channels, including WhatsApp, SMS and e-mail. The platform also integrates Artificial Intelligence and Microsoft Copilot capabilities, designed to s
Okomera Announces a Commercial Agreement With Servier to Use Its Tumor Miniaturization Technology for Cancer Research21.10.2026 08:00:00 CEST | Press release
Okomera reaches a key milestone in its industrial rollout with the first commercial installation of its integrated platform, combining hardware, software and biology, in the laboratories of an international pharmaceutical group. Servier will use Okomera’s technology to evaluate new therapeutic approaches in oncology and immuno-oncology. Okomera, a TechBio company pioneering personalized cancer care through a proprietary technology platform combining tumor mini-avatars, microfluidics, and AI-powered imaging, today announced the signing of a commercial agreement with Servier, an independent international pharmaceutical group, to use its technology in the development of new cancer treatments. With more than 90% of oncology drug candidates never reaching the market, identifying early on the therapeutic approaches most likely to succeed is a critical challenge for the pharmaceutical industry. Okomera’s technology helps precisely reduce this attrition, by steering development toward candidat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom